Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly and Boehringer Ingelheim Launch Biosimilar Lantus In UK, Germany

This article was originally published in The Pink Sheet Daily

Executive Summary

The cost of biosimilar Lantus to payers is at around a 15% discount to the originator product in the UK, but cost-savings are expected to vary across Europe as supply contracts with health insurers and hospitals are negotiated.


Related Content

Lilly’s Drops Peglispro Insulin; Now It Can Focus On Copycat Lantus
Amgen's First EU Biosimilar Filing Targets AbbVie's Humira
Market Snapshot: Under Pressure, Insulin Makers Pin Hopes On New Products
Sanofi Settlement With Lilly Paves The Way For Biosimilar Lantus
European Notebook: Salmonson Stays At CHMP Helm; Sandoz, AstraZeneca Build New Biologics Facilities
Novo Nordisk Plans Q1 Launch Of Long-Acting Insulin Tresiba
Lilly/BI Eye Diabetes Leadership In Expansive Risk-Sharing Collaboration


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts